Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[225Ac]Ac-Macropa-pertuzumab-PEG6-DM1
- Development stage
- Preclinical
- Lead developer
- University of Saskatchewan
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**[225Ac]Ac-Macropa-pertuzumab-PEG6-DM1** is a preclinical HER2-targeted antibody-drug radioconjugate for HER2-positive breast cancer. It consists of the anti-HER2 monoclonal antibody pertuzumab conjugated through a PEG6 linker to the maytansinoid microtubule inhibitor DM1 and labeled with the alpha-particle-emitting radionuclide actinium-225 through the Macropa chelator. Pertuzumab directs the construct to HER2-expressing cells and inhibits HER2 dimerization; intracellular DM1 contributes microtubule disruption, while actinium-225 delivers high-linear-energy-transfer alpha radiation. In mouse xenograft studies, the agent showed activity against trastuzumab-resistant and T-DM1-resistant HER2-positive breast cancer models, with complete remissions in HCC1954 tumors and substantial growth inhibition in JIMT-1 tumors. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41946831/))
- Other names
- [225Ac]Ac-Macropa-P-PEG6-DM1[225Ac]Ac-Macropa-pertuzumab-PEG6-DM1
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on [225Ac]Ac-Macropa-pertuzumab-PEG6-DM1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [225Ac]Ac-Macropa-pertuzumab-PEG6-DM1.